DR6.F - ACADIA Pharmaceuticals Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
46.15
+5.99 (+14.90%)
At close: 4:33PM CET
Stock chart is not supported by your current browser
Previous Close40.16
Open41.50
Bid45.38 x 30000
Ask45.79 x 30000
Day's Range41.50 - 47.46
52 Week Range12.76 - 47.46
Volume600
Avg. Volume26
Market Cap7.072B
Beta (3Y Monthly)2.82
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Why This Highflying Biotech Stock Zoomed Near A Profit-Taking Zone
    Investor's Business Daily

    Why This Highflying Biotech Stock Zoomed Near A Profit-Taking Zone

    Shares of Acadia Pharmaceuticals popped Thursday after the biotech company's psychosis treatment succeeded in a late-stage study — sending Acadia stock near a profit-taking zone.

  • 3 Monster Growth Stocks That Are Still in the Buy Zone
    TipRanks

    3 Monster Growth Stocks That Are Still in the Buy Zone

    With the holiday season kicking off, investors are shopping the Street for growth stocks. Stocks of this kind have a clear runway for growth, capable of delivering massive returns in the years to come. No wonder they are topping wish lists. However, in a year that has seen the market reach record highs, tracking down these names is becoming harder and harder to do. But don’t sound the alarm bells just yet. Wall Street pros remind investors that stocks with outsized growth prospects are still out there. In an attempt to lock down these compelling investment opportunities, we turned to TipRanks. The platform’s Stock Screener tool was able to scan the Street for the crème-de-la-crème. We mean the tickers offering up serious upside potential from current levels. Let’s get started. GDS Holdings Ltd (GDS)At a 103% year-to-date gain, all eyes are on GDS Holdings. This combined with a solid Q3 performance and strong long-term growth narrative has made the Chinese data center developer and operator a must-have name among several analysts. During the third quarter, the company saw revenue of RMB1,066 million, inching past the consensus estimate by about a percent. On top of this, service revenue increased 41% year-over-year and net loss narrowed from the prior-year quarter. That being said, Cowen & Co. analyst Colby Synesael points to its positioning in terms of demand as a key takeaway. “We believe the company continues to be well positioned in what is arguably the strongest data center market in the world and is taking the right steps to secure significantly more supply in its major markets as it prepares for even stronger demand in 2020,” he commented. Despite the five-star analyst’s prediction of continued macro and trade-driven volatility, he believes shares are set to climb higher in 2020. Taking this into consideration, Synesael reiterated his Outperform rating and bumped up the price target from $53 to $65. This bolstered target lends itself to a 39% potential twelve-month gain. (To watch Synesael’s track record, click here)Meanwhile, RBC Capital’s Jonathan Atkin cites the development pipeline as placing GDS on an upward trajectory. With GDS recently getting the go-ahead for 13,000 square meters of downtown capacity in Shanghai and its potential purchase of a second site in Hong Kong, total capacity lands at 230,000 square meters. “We believe, based on our discussions with industry contacts, that there is significant progress yet to come for additional edge-of-town deployments as well as new Tier 1 markets,” he noted. As a result, Atkin is staying with the bulls. Not to mention he lifted the price target by 40% to $62, indicating 32% upside potential. (To watch Atkin’s track record, click here)Similarly, the rest of the Street has been impressed by GDA. 100% Street support implies a clear message: the stock is a Strong Buy. In addition, the $61 average price target puts the upside potential at 31%.(See GDS Holdings stock analysis on TipRanks)    ACADIA Pharmaceuticals, Inc. (ACAD)ACADIA Pharmaceuticals wants to help patients battling central nervous system (CNS) disorders. When we say this name has soared year-to-date, we aren’t kidding. We’re talking 180% here. Still, analysts think that this is just the beginning.On November 25, ACAD released topline results from the ADVANCE Phase 2 trial of its pimavanserin drug in schizophrenia patients. According to the data, patients given the treatment witnessed a great improvement in Negative Symptom Assessment-16 (NSA-16) total score compared to the placebo. However, the results were somewhat of a mixed bag as it failed to demonstrate a superior performance vs the placebo in terms of the Personal and Social Performance (PSP) scale. Nonetheless, Cowen’s Ritu Baral maintains a bullish thesis. “Overall, we view these results to have little impact on ACAD shares due to the earlier stage of this program and the smaller market size of schizophrenia patients with predominant negative symptoms relative to pimavanserin's new opportunity in Dementia-related psychosis (DRP),” she explained. The five-star analyst goes on to cite the Phase 3 HARMONY study in DRP patients as an upcoming catalyst. If this wasn’t promising enough, its trofinetide drug to treat patients with Rett Syndrome could also drive substantial gains. Rett Syndrome is a primarily female congenital neuro-developmental CNS disorder affecting cognition and sensorimotor function. Given that the drug demonstrated statistically significant results in a Phase 2 study as well as its potential to treat Fragile X Syndrome or traumatic brain injuries, Baral kept the recommendation as Outperform. Based on the $66 price target, she sees 46% upside potential in store. (To watch Baral’s track record, click here)In general, Wall Street likes what it’s seeing. 11 Buys and 2 Holds received in the last three months add up to a Strong Buy analyst consensus. At the $56 average price target, shares could surge 23% in the next twelve months. (See ACADIA Pharmaceuticals stock analysis on TipRanks) Pegasystems Inc. (PEGA)Pegasystems offers cloud-based software for customer engagement and other operational needs, with its low-code application development platform allowing organizations to quickly build apps to meet their customer and employee requirements. Considering the noteworthy 62% jump year-to-date, one analyst is betting that PEGA will come out on top in the long-run.Wedbush analyst Steven Koenig was impressed by PEGA’s third quarter results. Despite the fact that investments in cloud infrastructure and government certifications weighed on EPS, annual contract value growth of 20% year-over-year and a 7% revenue gain landed right in-line with consensus estimates. While PEGA may be impacted by the shift to a cloud-first model, the analyst expects this change to pay off long-term, deeming the software company a “Wedbush Best Idea”.“Investments in sales talent and capacity should drive better penetration of large accounts, perhaps the key to lifting underlying growth rates beyond the 20% level. With shares trading at 5.6x EV/FY20E revenue and key metrics inflecting positively, we see PEGA as a top pick into FY20 for GARP-oriented software investors,” he wrote in a note to clients. Bearing this in mind, Koenig tells investors his conclusion that PEGA will ultimately outperform remains unchanged. Along with the recommendation, the five-star analyst kept the price target at $95. This conveys his confidence in PEGA’s ability to rise 22% in the coming twelve months. (To watch Koenig’s track record, click here) Looking at the consensus breakdown, it has been relatively quiet in terms of analyst activity. In the previous three months, PEGA racked up 1 Buy rating, giving it a Moderate Buy consensus. Additionally, the average price target of $95 implies 22% upside potential. (See Pegasystems stock analysis on TipRanks)

  • TEST Business Wire Releases

    ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia

    ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced positive top-line results from its ADVANCE study, a 26-week, randomized, double-blind, placebo-controlled study in 403 patients. ADVANCE evaluated the efficacy and safety of adjunctive pimavanserin treatment in patients with predominantly negative symptoms of schizophrenia who have achieved adequate control of positive symptoms with their existing antipsychotic treatment. No drug is approved by the FDA for the treatment of the negative symptoms of schizophrenia.

  • Investopedia

    The Medicines Company Soars Amid Acquisition Whispers

    The Medicines Company climbed to an all-time high Tuesday after takeover rumors surfaced. Play the momentum using these tactical ideas.

  • IBD Stock Of The Day Breaks Out As It Stares Down A Massive Opportunity
    Investor's Business Daily

    IBD Stock Of The Day Breaks Out As It Stares Down A Massive Opportunity

    Acadia Pharmaceuticals is the IBD Stock Of The Day as investors look ahead to a presentation of the biotech company's psychosis treatment, a drug known by the test name of pimavanserin.

  • Hedge Funds Are Betting On ACADIA Pharmaceuticals Inc. (ACAD) Again
    Insider Monkey

    Hedge Funds Are Betting On ACADIA Pharmaceuticals Inc. (ACAD) Again

    We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]

  • Benzinga

    'Pleasantly Surprised' Acadia Analysts See Blockbuster Potential For Pimavanserin In Dementia Psychosis

    H.C. Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Acadia with a $60 price target. Acadia delivered another pleasant surprise for investors by way of a positive interim analysis from the Phase 3 HARMONY study, which showed pimavanserin's statistically superior efficacy compared to placebo in time to relapse of dementia-related psychosis, Fein said in a Tuesday note. The analyst sees the dementia-related psychosis opportunity alone as sufficient to fuel pimavanserin growth in the foreseeable future.

  • Is Acadia Pharmaceuticals a Good Biotech Stock to Buy Now?
    Motley Fool

    Is Acadia Pharmaceuticals a Good Biotech Stock to Buy Now?

    Lackluster sales of Nuplazid could finally take flight next year.

  • Why Acadia Pharmaceuticals Stock Skyrocketed Today
    Motley Fool

    Why Acadia Pharmaceuticals Stock Skyrocketed Today

    Acadia's flagship drug notched a key late-stage win today.

  • Why This Biotech Stock Just Rocketed 63% After Hitting A 4-Year High
    Investor's Business Daily

    Why This Biotech Stock Just Rocketed 63% After Hitting A 4-Year High

    Shares of Acadia Pharmaceuticals rocketed Monday after the biotech company said its psychosis treatment met its key goal in a Phase 3 test. The drug already sells under the name Nuplazid.

  • What Happened in the Stock Market Today
    Motley Fool

    What Happened in the Stock Market Today

    Read why AT&T and ACADIA Pharma stood out on a roller-coaster day for the broader markets.

  • Benzinga

    Acadia Stops Nuplazid Study Early After Drug Shows 'Statistically Superior Efficacy' In Dementia-Related Psychosis

    Acadia, an actively traded mid-cap biotech, said Monday that it will stop the Phase 3 HARMONY study early based on the recommendation of the independent data monitoring committee that reviewed data from the planned interim analysis. The HARMONY study is evaluating pimavanserin for the treatment of dementia-related psychosis. Interim analysis of data showed the study met its primary endpoint by demonstrating a highly statistically significant longer time to the relapse of psychosis with pimavanserin compared to placebo.

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For September 9, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. ACADIA Pharmaceuticals (NASDAQ: ACAD ) shares ...

  • TheStreet.com

    [video]Acadia Pharmaceuticals Surges on Positive Trial Results for Psychosis Treatment

    Acadia Pharmaceuticals rockets higher after it announces it has ended a phase 3 trial of its dementia-related psychosis treatment, pimavanserin, on better-than-expected results.

  • MarketWatch

    Acadia Pharmaceuticals stock rockets after late-stage trial of pimavanserin mets primary endpoint

    Shares of Acadia Pharmaceuticals Inc. rocketed 87% toward a 4-year high in premarket trading Monday, after the biopharmaceutical company said a phase 3 trial of its treatment for dementia-related psychosis met its primary endpoint. The company said pimavanserin achieved "robust statistical superiority" over placebo, with longer time to relapse of psychosis with pimavanserin compared with placebo. Acadia said the study will be stopped early based on the study's findings. The company plans to meet with the Food and Drug Administration regarding a supplemental new drug application (NDA) submission in 2020. The stock, on track to open at the highest price seen during regular-session hours since August 2015, has run up 47.2% year to date through Friday, while the iShares Nasdaq Biotechnology ETF has gained 6.0% and the S&P 500 has advanced 18.8%.

  • Why Acadia Pharmaceuticals Stock Is Crushing It Today
    Motley Fool

    Why Acadia Pharmaceuticals Stock Is Crushing It Today

    Great Q2 results powered by strong momentum for antipsychotic drug Nuplazid have investors fired up.

  • Acadia Pharmaceuticals Beats Expectations in Q2
    Motley Fool

    Acadia Pharmaceuticals Beats Expectations in Q2

    Nuplazid picked up momentum in the second quarter, enabling Acadia to up its full-year 2019 outlook.

  • Acadia Pharmaceuticals (ACAD) Q2 2019 Earnings Call Transcript
    Motley Fool

    Acadia Pharmaceuticals (ACAD) Q2 2019 Earnings Call Transcript

    ACAD earnings call for the period ending June 30, 2019.

  • Benzinga

    The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 22) Acasti Pharma Inc (NASDAQ: ACST ) Apellis Pharmaceuticals ...

  • Reuters

    Acadia's schizophrenia treatment misses late-stage main goal; shares fall 16%

    In the study, 396 patients with moderate-to-severe psychotic symptoms were given Acadia's treatment pimavanserin or placebo as an add-on to their current antipsychotic treatment, the company said. Adding pimavanserin to existing antipsychotic treatment showed a consistent trend in improvement of psychotic symptoms, however, the results did not show statistical significance in achieving the main goal, Acadia said.

  • TheStreet.com

    Acadia Falls Sharply in After-Hours Trading After Schizophrenia Drug Fails Study

    Stock drops as Pimavanserin study finds no statistically significant improvement in adult schizophrenia patients.

  • Why Acadia Pharmaceuticals Stock Slumped in April
    Motley Fool

    Why Acadia Pharmaceuticals Stock Slumped in April

    The contentious drug-pricing debate weighed on Acadia Pharmaceuticals' shares last month.

  • Acadia Pharmaceuticals (ACAD) Q1 2019 Earnings Call Transcript
    Motley Fool

    Acadia Pharmaceuticals (ACAD) Q1 2019 Earnings Call Transcript

    ACAD earnings call for the period ending March 31, 2019.